Completed PHASE1 INTERVENTIONAL 2-arm NCT04784000

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

A Phase 1 Study Assessing the Effect of Carbamazepine, a P-Glycoprotein Inducer, on the Pharmacokinetics of AT-527 in Healthy Adult Subjects

Sponsor: Atea Pharmaceuticals, Inc.

Conditions Healthy Volunteer Study

Interventions Period 1: AT-527 550 mg Period 2: carbamazepine Period 3: AT-527 1100 mg + carbamazepine Period 3: AT-527 550 mg + carbamazepine

Updated 4 times since 2021 Last updated: Jul 27, 2021 Started: Mar 1, 2021 Primary completion: Apr 10, 2021 Completion: Apr 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04784000, this PHASE1 trial focuses on Healthy Volunteer Study and remains completed. Sponsored by Atea Pharmaceuticals, Inc., it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Apr 2021 — Sep 2021 [monthly]

Recruiting PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Data source: Atea Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada